Trials / Unknown
UnknownNCT00722930
Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma
Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the complete clinical response rate according to the International Working Group criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients with high-risk follicular lymphoma with either partial or complete response to R-CHOP induction chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Y90 Ibritumomab Tiuxetan | Consolidation with Y90 Ibritumomab Tiuxetan |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-04-01
- Completion
- 2013-04-01
- First posted
- 2008-07-28
- Last updated
- 2008-07-28
Locations
11 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00722930. Inclusion in this directory is not an endorsement.